2lkq: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==NMR structure of the lambda 5 22-45 peptide== | |||
<StructureSection load='2lkq' size='340' side='right' caption='[[2lkq]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[2lkq]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2LKQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2LKQ FirstGlance]. <br> | |||
==Disease== | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2lkq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2lkq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2lkq RCSB], [http://www.ebi.ac.uk/pdbsum/2lkq PDBsum]</span></td></tr> | ||
</table> | |||
== Disease == | |||
[[http://www.uniprot.org/uniprot/IGLL1_HUMAN IGLL1_HUMAN]] Defects in IGLL1 are the cause of agammaglobulinemia type 2 (AGM2) [MIM:[http://omim.org/entry/613500 613500]]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B-cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life. | [[http://www.uniprot.org/uniprot/IGLL1_HUMAN IGLL1_HUMAN]] Defects in IGLL1 are the cause of agammaglobulinemia type 2 (AGM2) [MIM:[http://omim.org/entry/613500 613500]]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B-cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life. | ||
== Function == | |||
[[http://www.uniprot.org/uniprot/IGLL1_HUMAN IGLL1_HUMAN]] Critical for B-cell development.<ref>PMID:9419212</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
During B cell differentiation in the bone marrow, the expression and activation of the pre-B cell receptor (pre-BCR) constitutes a crucial checkpoint for B cell development. Both constitutive and ligand-dependent pre-BCR activation modes have been described. The pre-BCR is constituted of an immunoglobulin heavy chain (Igmu) and of a surrogate light chain (SLC) composed of the invariant lambda5 and VpreB proteins. We previously showed that Galectin-1 (GAL1), produced by bone marrow stromal cells, is a pre-BCR ligand that induces receptor clustering, leading to efficient pre-BII cell proliferation and differentiation. GAL1 interacts with the pre-BCR via the unique region of lambda5 (lambda5-UR). Here we investigated the solution structure of a minimal lambda5-UR motif that interacts with GAL1. This motif adopts a stable helical conformation that docks onto a GAL1 hydrophobic surface adjacent to its carbohydrate-binding site (CBS). We identified key hydrophobic residues from the lambda5-UR as crucial for the interaction with GAL1 and for pre-BCR clustering. These residues involved in GAL1-induced pre-BCR activation are different to those essential for autonomous receptor activation. Overall, our results indicate that constitutive and ligand-induced pre-BCR activation could occur in a complementary manner. | |||
Structural basis for galectin-1-dependent pre-B cell receptor (pre-BCR) activation.,Elantak L, Espeli M, Boned A, Bornet O, Bonzi J, Gauthier L, Feracci M, Roche P, Guerlesquin F, Schiff C J Biol Chem. 2012 Nov 2. PMID:23124203<ref>PMID:23124203</ref> | |||
== | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
<references | </div> | ||
[[Category: Boned, A | == References == | ||
[[Category: Bornet, O | <references/> | ||
[[Category: Breton, C | __TOC__ | ||
[[Category: Elantak, L | </StructureSection> | ||
[[Category: Espeli, M | [[Category: Boned, A]] | ||
[[Category: Feracci, M | [[Category: Bornet, O]] | ||
[[Category: Guerlesquin, F | [[Category: Breton, C]] | ||
[[Category: Roche, P | [[Category: Elantak, L]] | ||
[[Category: Schiff, C | [[Category: Espeli, M]] | ||
[[Category: Feracci, M]] | |||
[[Category: Guerlesquin, F]] | |||
[[Category: Roche, P]] | |||
[[Category: Schiff, C]] | |||
[[Category: B cell development]] | [[Category: B cell development]] | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
[[Category: Pre-bcr]] | [[Category: Pre-bcr]] | ||
